Study: Multiple Cannabis Compounds Found to Target Key Skin Cancer Growth Pathways
- The study identified multiple cannabis-derived compounds that can disrupt key biological pathways (EGFR, BRAF V600E, TGF-β) involved in skin cancer progression.
- Researchers used computational methods, including molecular docking and simulations, to evaluate 49 cannabis phytochemicals for their binding strength and stability with cancer-related targets.
- Several compounds demonstrated strong, stable interactions with cancer proteins and showed favorable safety and drug-like properties in pharmacokinetic modeling.
- While the findings are based on computer modeling, the study provides a basis for future laboratory research exploring cannabis-based multitarget therapies for skin cancer treatment.
According to a new study published in the journal Pharmaceuticals, numerous compounds derived from cannabis may help disrupt multiple biological pathways involved in the progression of skin cancer. The study was conducted by researchers from Moulay Ismail University, United Arab Emirates University and Hassan II University of Casablanca. Their work focused on three major signaling pathways known to fuel skin cancer growth and spread: EGFR, BRAF V600E and TGF-β. These pathways play a central role in tumor cell proliferation, invasion and metastasis.
Using advanced computer-based modeling, the research team analyzed 49 phytochemicals found in Cannabis sativa to determine how effectively they might bind to and block these cancer-driving targets. The evaluation included molecular docking to measure binding strength, as well as pharmacokinetic and safety modeling to assess how the compounds might behave in the body.
Several cannabis-derived compounds demonstrated strong binding affinity to the targeted proteins, forming stable interactions with critical regions of the cancer-related receptors. The team then conducted extended molecular dynamics simulations lasting 200 nanoseconds to examine how stable these interactions remained over time. Additional binding energy calculations further supported the strength and stability of the most promising compounds.
According to the findings, multiple cannabis phytochemicals showed favorable safety and drug-like properties in the simulations, suggesting they could serve as multitarget modulators against key oncogenic signals involved in skin cancer.
While the results are based on computational modeling rather than laboratory or clinical testing, the researchers say the data provide a mechanistic foundation for future in vitro studies and the potential development of cannabis-derived therapies aimed at targeted skin cancer treatment.
The authors conclude that cannabis may represent a promising source of compounds capable of interfering with multiple cancer-promoting pathways simultaneously, though further experimental validation is needed.